ArticleTranslational cancer research2020
The lncRNAs MIR600HG and TSPOAP1-AS1 may potentially act as biomarkers for predicting pancreatic cancer.
Article in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 6 citations in OpenAlex.
- lncRNAs: key player in Aβ deposition.RNA biology · 2026Review
- TSPOAP1-AS1: A Novel Biomarker for the Prognosis and Therapeutic Target in Cervical Cancer.Combinatorial chemistry & high throughput screening · 2026Article
- LncRNA MIR600HG inhibits laryngeal cancer development by mediating the miR-424-5p/BTG2 axis.Cancer science · 2025Article
- The road to overcome pancreatic cancer: Where are we?Heliyon · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study was to assess long non-coding RNAs (lncRNAs) as biomarkers of pancreatic cancer (PC).
methodsThe Cancer Genome Atlas (TCGA) database was used to obtain the expression profiles of lncRNAs and clinical characteristics of PC patients. Then, differentially expressed lncRNAs (DElncRNAs) between tumor and normal tissue samples were determined. A pancreatic cancer related lncRNA prognostic model was established by univariate and multiple Cox regression analyses of all DElncRNA expression data. The specificity and sensitivity of the developed prognostic model were evaluated by Receiver operating characteristic (ROC) curves analysis. A lncRNA-mRNA co-expression network using Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO) functional enrichment analyses was built to predict the potential biological functions of lncRNAs.
resultsA total of 178 DElncRNAs were screened from TCGA. Through univariate and multiple Cox regression analyses, a two-lncRNA (MIR600HG and TSPOAP1-AS1) predictive model was established. Further analysis determined a risk score that predicted prognosis independently of other clinicopathological factors. ROC curves analysis showed that the lncRNA signature model had high sensitivity and specificity. GO and KEGG functional enrichment analysis revealed that the two-lncRNA signature was mostly concentrated in PC related biological processes (BP).
conclusionsThese data provide evidence that MIR600HG and TSPOAP1-AS1 may serve as potential biomarkers to predict PC prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.